mRNA-1365

BIOLOGICAL2 trials

Sponsors

Moderna Inc., ModernaTX, Inc.

Conditions

Acute lower respiratory infectionHuman MetapneumovirusRespiratory Syncytial Virus

Phase 1

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Active, not recruitingNCT05743881

ModernaTX, Inc.Human Metapneumovirus, Respiratory Syncytial Virus

Start: 2023-02-15End: 2026-09-30Updated: 2025-11-24

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months

CompletedCTIS2022-502022-41-00

Moderna Inc.Acute lower respiratory infection

Start: 2024-05-28End: 2024-12-18Target: 248Updated: 2024-09-24